Annexon (NASDAQ:ANNX) Announces Earnings Results, Misses Estimates By $0.07 EPS

Annexon (NASDAQ:ANNX) announced its quarterly earnings data on Monday. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.07), Zacks reports.

Annexon Trading Up 4.9%

Shares of Annexon stock opened at $1.78 on Monday. The firm has a market capitalization of $195.73 million, a PE ratio of -1.70 and a beta of 1.24. The firm’s 50 day moving average is $2.00 and its 200 day moving average is $3.82. Annexon has a 1 year low of $1.29 and a 1 year high of $7.85.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reaffirmed a “buy” rating and issued a $16.00 price target on shares of Annexon in a research note on Tuesday, March 4th.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.